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Abstract 
AIM: The aim of this study was to determine cytotoxic activity of BornUSU I or Boronhafagama I (1,5-bis(4-
hydroxyphenyl)-3-oxa-1,5-diaza-2,4-diboropentane-2,4-diol) as a boron derivate compounds which are boron 
neutron captured theraphy (BNCT) candidates. 
METHODS: The T47D cells were treated by BornUSU I, and Tamoxifen as a positive control. The in vitro study 
was using MTT method with the incubation period for 24h and 48h. All data were determined using viability of 
cells equation for showing each IC50 value. 
RESULTS: The IC50 value of BornUSU I and Tamoxifen were 72.61 ± 0.82 µM and 10.62 ± 0.06 µM for 24 h 
incubation period, and for the 48 h incubation period were 44.63 ± 0.23 µM and 7.79 ± 0.05 µM. The 48 h 
incubation period results showed the lowest IC50 value. 
CONCLUSION: The results reveal that BornUSU I provide effective as anticancer, especially for breast cancer 
treatment. 
 
 
 
 
 
 
 
 
Introduction 
 
Breast cancer is the most incidence cancer 
and the second leading cause of cancer death among 
females [1]. Moreover, breast cancer ranks as the fifth 
cause of death from cancer overall (522,000 deaths), 
is the most frequent cause of cancer death in women 
in less developed countries (324,000 deaths, 14.3% of 
total), and the second cause of cancer death in 
developed countries (198,000 deaths, 15.4%) after 
lung cancer. A recent study publishedwhich breast 
cancer is leading in the estimated new cancer cases, 
and the second most common death cause among 
women suffering from cancer in the USA [2]. 
 
Boron Neutron Capture Therapy (BNCT) is an 
advanced form of radiotherapy technique which is 
potentially superior to all conventional techniques for 
cancer treatment, as it is targeted at killing individual 
cancerous cells with minimal damage to surrounding 
healthy cells [3]. Boronic compounds has been 
previously used in imaging and medicinal chemistry 
offering unique advantages associated with its low 
toxicity and stability [4]. 
BornUSU I (1,5-bis(4-hydroxyphenyl)-3-oxa-
1,5-diaza-2,4-diboropentane-2,4-diol) or 
Boronhafagama I. The chemical structures of 
BornUSU I and tamoxifen are showed in Figure 1. 
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Figure 1: Structure of A) BornUSU I and B) Tamoxifen 
 
 
Material and Methods 
 
Chemicals Material 
BornUSU I was obtained from Dr. Hari 
Purnomo, M.S., Apt. Chemicals used were distilled 
water from Water One-OneMed (Indonesia), DMSO 
and [3-(4,5-dimethylthiazole-2-yl)-2,5 
diphenyltetrazolium bromide] (MTT) from Sigma - 
Aldrich (USA). 
 
Cytotoxicity Assay 
The cells were treated by BornUSU I and 
tamoxifen. In this test, T47D cell line was grown in 
RPMI-1640 medium, medium containing 10% Fetal 
Bovine Serum (Gibco), 1% penicillin-streptomycine 
(Gibco), and fungizone 0.5% (Gibco) in a petridish in a 
humidified atmosphere (5% CO2) at 37°C. The 
inoculums seeded at 1 x 10
4
 cells/mL at an optimal 
volume of 0.1 mL per well. After 24 h incubation, the 
medium was discharged and treated by BornUSU I 
and tamoxifen. After incubation 24 h and 48 h, the 
cells were incubated with 0.5 mg/mL MTT for 4 h in 
37°C. Viable cells reacted with MTT to produce purple 
formazan crystals. After 4 h, SDS 10% as stopper 
(Sigma) in 0.01N HCl (Merck) was added to dissolve 
the formazan crystals. The cells were incubated for 24 
h in room temperature and protected from light. After 
incubation, absorbance was measured using ELISA 
reader at λ 595 nm. The data which were absorbed 
from each well were converted to percentage of viable 
cells [5], [6], [7], [8], [9]. The equation to determine 
viability of cells: 
 
            
                             
                                 
        
 
Statistic Analysis 
All cytotoxic data were analyzed using SPSS 
21 software by probit analysis. 
 
Results  
 
Inhibitory Concentration 50% (IC50) 
MTT method was used to determine cell 
viability after incubation for 24h and 48h. The two 
different period of incubation was used to determine 
which one can give the lowest IC50 value. Cytotoxic 
activity of BornUSU I and tamoxifen were showed in 
Table 1. 
Table 1: IC50 value of BornUSU I and tamoxifen towards T47D 
breast cancer cells 
Treatment 
IC50 (µM) 
24h 48h 
BornUSU I 72.61 ± 0.82 44.63 ± 0.23 
Tamoxifen 10.62 ± 0.06 7.79 ± 0.05 
 
Based on the results, it can be seen that 
T47D cell showed the inhibition of cell growth due to 
the influenced of BornUSU I and tamoxifen. The IC50 
values with BornUSU I treatment for each 24 h and 48 
h incubation were obtained 72.61 ± 0.82 µM and 
44.63 ± 0.23 µM, also the IC50 values with tamoxifen 
treatment for each 24 h and 48 h incubation were 
obtained 10.62 ± 0.06 µM and 7.79 ± 0.05 µM. The 
results showed that IC50 values for 48h incubation 
had smaller values than 24 h incubation. 
 
 
Discussion 
 
The principle of the MTT method is cellular 
reduction reaction based on the breakdown of yellow 
MTT tetrazolium salts into purplish blue formazan 
crystals. This color changing is an indicator of cell 
proliferation. The mitochondria of proliferating cells will 
absorb MTT so these cells will turn purple due to the 
formation of tetrazolium crystals (formazan) [10]. 
The results showed that IC50 values for 48h 
incubation had smaller values than 24 h incubation. 
More decreasing of IC50 value means the cytotoxic 
activity is higher [11]. Barry et al., in 2014, reported 
the need for an efficient delivery of boron agents to 
overcome the challenge of clinical development [12]. 
In this study, T47D cell line was used to determine 
BornUSU I had the cytotoxicity activity as the clinical 
developing of anticancer agent. T47D breast cancer 
cells have positive molecular characteristics of 
Estrogen Receptor alpha (ER-α) overexpression [13]. 
Tamoxifen has become a first-line therapy for patients 
with breast cancer risk with ER-α for both pre and 
postmenopausal patients, as well as for advanced 
breast cancer patients [14]. 
In conclusion, BornUSU I is boron derivate 
compounds. BornUSU I has the cytotoxic activity and 
it is potential to develop as more effective anticancer 
agent. 
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